GB Therapeutics Ltd. Changes Its Name To Cita NeuroPharmaceuticals Inc.
10/19/2005 5:13:17 PM
More...
|
GB Therapeutics Ltd. Acquires Phase 3 Parkinson's Disease Molecule From Chiesi Farmaceutici SpA
10/19/2005 5:12:34 PM
More...
|
GB Therapeutics Ltd. Acquires License For A Phase 2 Neuropathic Pain molecule
10/19/2005 5:11:43 PM
More...
|
GB Therapeutics Ltd. Obtains US Patent No. 6,677,374 B2 For Nitric Oxide Mimetic Compounds For Neuroprotection In Neurological Or Cognitive Conditions
10/19/2005 5:10:01 PM
More...
|
GB Therapeutics Ltd.'s GT 1061, Targeted To Alzheimer's Disease, Proceeds To Human Safety Testing Subsequent To FDA Review Of First IND
10/19/2005 5:09:36 PM
More...
|
GB Therapeutics Ltd. Obtains Canadian Regulator's Approval To Start Human Safety Testing For GT 1061, Targeted At Alzheimer's Disease
10/19/2005 5:09:23 PM
More...
|